An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
- A Gentler Cell Line Selection Method Using microRNA
- Controls For Retrieval-Augmented Generation In GxP
- Implementing AI Solutions In GMP While Managing Risk
- Implementing And Optimizing Your eQMS
- A Much-Improved Approach For Understanding And Managing Safety Risks
- CSV Assumes The AI System Sits Still — It Doesn't.
- July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
GUEST COLUMNISTS
-
A Gentler Cell Line Selection Method Using microRNA
Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.
-
Controls For Retrieval-Augmented Generation In GxP
Validation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.
-
Implementing AI Solutions In GMP While Managing Risk
When using artificial intelligence in GMP settings, risk management extends far beyond validation. This discussion explores moving AI solutions out of the pilot phase.
-
Implementing And Optimizing Your eQMS
This article addresses everything that follows the signed contract for an eQMS: how a system is configured, validated, adopted, and maintained.
-
A Much-Improved Approach For Understanding And Managing Safety Risks
Learn how causal mechanism and effect analysis (CMEA) and its principles can be used to develop and maintain safer working environments in the pharma/biotech and medical device industries.
-
CSV Assumes The AI System Sits Still — It Doesn't.
The computer system validation playbook was written for software that holds its shape. AI doesn't. Validating it has to become an act of governance.
-
July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.
BIOSIMILAR WHITE PAPERS
-
Why Choose Robotic Processing For Small Batch Aseptic Filling
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing5/12/2025
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
ADC Manufacturing: Practices, Challenges, And The Road Ahead6/15/2026
ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.
-
Perfusion Cell Line Development For Intensified Processes5/5/2025
The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.
-
Optimizing Safety Measures For rAAV Therapies10/11/2024
Explore common process-related impurities found in recombinant Adeno-Associated Virus (rAAV) vectors and the analytical testing methods used for these residuals.
-
Reliability In Bioprocessing Is Your Competitive Advantage9/11/2026
Equipment reliability is a prerequisite for realizing value from digital transformation, automation, and data-driven initiatives in bioprocess manufacturing.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- STADA And SBP Group Launch Strategic Biosimilars Partnership, Including A Biosimilar To Keytruda
- Meitheal Pharmaceuticals Announces FDA Approval Of High-Concentration Formulation Of YUSIMRY, A Biosimilar To Humira
- Teva Continues Biosimilar Momentum With U.S. FDA Approval Of DEGEVMA™ (denosumab-adet), A Biosimilar To Xgeva® (denosumab)
- PhRMA Statement On The Biosimilar User Fee Act (BsUFA) IV Performance Goals Letter
- Formycon Sets Benchmark In Biosimilar Development: Scientific Foundation Of The Innovative Development Program For FYB206 Published In The Journal BioDrugs
- OPM Biosciences Launches Integrated Cell Culture Media-To-Manufacturing Platform For Biosimilar Development
- Biocon's Pertuzumab Becomes First Biosimilar To Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach
- Sandoz Announces Collaboration With mAbxience To Expand Patient Access To Life-Enhancing Biosimilar Medicines
NEWSLETTER ARCHIVE
- 09.24.26 -- Navigating The Regulatory Space To Biosimilar Approval
- 09.17.26 -- Your Collaborator: mAb Productivity And Robustness
- 09.17.26 -- A Much-Improved Approach For Managing Safety Risks
- 09.16.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises
- 09.10.26 -- U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing